Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report

Cyril Pottier, Evadnie Rampersaud, Matt Baker, Gang Wu, Joanne Wuu, Jacob L. McCauley, Stephan Zuchner, Rebecca Schule, Christin Bermudez, Sumaira Hussain, Anne Cooley, Marielle Wallace, Jinghui Zhang, J. Paul Taylor, Michael Benatar, Rosa V Rademakers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80% reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
DOIs
StateAccepted/In press - Mar 20 2018

Fingerprint

Amyotrophic Lateral Sclerosis
Mutation
Inheritance Patterns
Genetic Testing
Frontotemporal Dementia With Motor Neuron Disease
Messenger RNA
Research
Genes

Keywords

  • Amyotrophic lateral sclerosis
  • compound heterozygous
  • frontotemporal dementia
  • mutation
  • optineurin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium : a case report. / Pottier, Cyril; Rampersaud, Evadnie; Baker, Matt; Wu, Gang; Wuu, Joanne; McCauley, Jacob L.; Zuchner, Stephan; Schule, Rebecca; Bermudez, Christin; Hussain, Sumaira; Cooley, Anne; Wallace, Marielle; Zhang, Jinghui; Taylor, J. Paul; Benatar, Michael; Rademakers, Rosa V.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 20.03.2018, p. 1-3.

Research output: Contribution to journalArticle

Pottier, C, Rampersaud, E, Baker, M, Wu, G, Wuu, J, McCauley, JL, Zuchner, S, Schule, R, Bermudez, C, Hussain, S, Cooley, A, Wallace, M, Zhang, J, Taylor, JP, Benatar, M & Rademakers, RV 2018, 'Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, pp. 1-3. https://doi.org/10.1080/21678421.2018.1452947
Pottier, Cyril ; Rampersaud, Evadnie ; Baker, Matt ; Wu, Gang ; Wuu, Joanne ; McCauley, Jacob L. ; Zuchner, Stephan ; Schule, Rebecca ; Bermudez, Christin ; Hussain, Sumaira ; Cooley, Anne ; Wallace, Marielle ; Zhang, Jinghui ; Taylor, J. Paul ; Benatar, Michael ; Rademakers, Rosa V. / Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium : a case report. In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018 ; pp. 1-3.
@article{835390f8ce8143e6bcb3800fb21895af,
title = "Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report",
abstract = "Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80{\%} reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.",
keywords = "Amyotrophic lateral sclerosis, compound heterozygous, frontotemporal dementia, mutation, optineurin",
author = "Cyril Pottier and Evadnie Rampersaud and Matt Baker and Gang Wu and Joanne Wuu and McCauley, {Jacob L.} and Stephan Zuchner and Rebecca Schule and Christin Bermudez and Sumaira Hussain and Anne Cooley and Marielle Wallace and Jinghui Zhang and Taylor, {J. Paul} and Michael Benatar and Rademakers, {Rosa V}",
year = "2018",
month = "3",
day = "20",
doi = "10.1080/21678421.2018.1452947",
language = "English (US)",
pages = "1--3",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium

T2 - a case report

AU - Pottier, Cyril

AU - Rampersaud, Evadnie

AU - Baker, Matt

AU - Wu, Gang

AU - Wuu, Joanne

AU - McCauley, Jacob L.

AU - Zuchner, Stephan

AU - Schule, Rebecca

AU - Bermudez, Christin

AU - Hussain, Sumaira

AU - Cooley, Anne

AU - Wallace, Marielle

AU - Zhang, Jinghui

AU - Taylor, J. Paul

AU - Benatar, Michael

AU - Rademakers, Rosa V

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80% reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.

AB - Homozygous loss-of-function mutations in optineurin (OPTN) are a rare cause of amyotrophic lateral sclerosis (ALS), whereas heterozygous loss-of-function mutations have been suggested to increase ALS disease risk. We report a patient with ALS and frontotemporal dementia (FTD) from the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium carrying compound heterozygous loss-of-function variants in OPTN. Quantitative real-time mRNA expression analyses revealed a 75–80% reduction in OPTN expression in blood in the OPTN carrier as compared to controls, suggesting at least partial nonsense-mediated decay of the mutant transcripts. This case report illustrates the diverse inheritance patterns and variable clinical presentations associated with OPTN mutations, and underscores the importance of complete OPTN gene screening in patients with ALS and related disorders, especially in the context of clinical genetic testing.

KW - Amyotrophic lateral sclerosis

KW - compound heterozygous

KW - frontotemporal dementia

KW - mutation

KW - optineurin

UR - http://www.scopus.com/inward/record.url?scp=85044301187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044301187&partnerID=8YFLogxK

U2 - 10.1080/21678421.2018.1452947

DO - 10.1080/21678421.2018.1452947

M3 - Article

C2 - 29558868

AN - SCOPUS:85044301187

SP - 1

EP - 3

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

ER -